Mentor Capital
Mentor Capital, Inc. is a private equity firm based in Ramona, California, that specializes in investments within the medical and social use cannabis sectors. Founded in 1985, Mentor Capital focuses on providing passive equity funding and liquidity to smaller cannabis companies, enabling them to access public markets through shelf IPOs and other investment avenues. The firm typically invests in companies with earnings and sales exceeding $40 million, taking significant stakes while allowing founders to maintain operational control. Mentor Capital aims to facilitate the application of cannabis for various medical conditions, including cancer-related issues, seizures, and chronic pain. The company has transitioned from its original focus on cancer investments to concentrate on the burgeoning cannabis market, seeking long-term cooperative financing solutions that offer founders more cash while retaining a smaller equity share. Through its unique capital structure, Mentor Capital strives to enhance shareholder value and encourage private cannabis firms to engage in partnerships that support their growth.
Top Stages
4 past transactions
eShiksa
Seed Round in 2019
eShiksa is a developer of an education management portal that streamlines the operations of educational institutions. The platform facilitates an efficient fee management system, allowing students and parents to pay various school and college fees online through a user-friendly mobile app or desktop interface. By providing a single window for accessing academic reports and financial transactions, eShiksa enhances the administrative capabilities of institutions, enabling them to manage, analyze, and report extensive data effectively. This system not only simplifies the fee collection process but also empowers institutional management with real-time access to critical financial data, thereby aiding in financial planning and business forecasting.
G Farma Labs
Venture Round in 2018
G Farma Labs supplies cannabis related products. That products include G Stik, G Drinks, Liquid Gold Vape Oil, chocolates, and cannabis pre-rolls. They also offer sprinkled with kief, and liquid goal CO2 extracted cannabis oil for the smoke.
GW Pharmaceuticals
Post in 2017
GW Pharmaceuticals plc is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of innovative therapeutics derived from its proprietary cannabinoid product platform. The company's primary product, Epidiolex, is an oral solution approved for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged one year and older in the United States, and under the name Epidyolex in the European Union for similar indications. Additionally, GW Pharmaceuticals markets Sativex for managing spasticity due to multiple sclerosis and is advancing various cannabinoid product candidates through clinical trials targeting conditions such as schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. Established in 1998, the company operates primarily in Europe, the United Kingdom, and the United States.
Bhang
Venture Round in 2014
Bhang Inc. specializes in the production and distribution of cannabis-infused products on a global scale. The company offers a diverse portfolio that includes more than 100 products, featuring gourmet chocolates, CBD gummies, capsules, e-liquids, tinctures, and pre-rolls, among others. Bhang focuses on utilizing high-quality ingredients to create medicated edibles that emphasize both quality and effectiveness. With a presence in key markets such as Canada and the United States, Bhang aims to cater to a wide range of consumer preferences within the evolving cannabis industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.